SEC Form 4 · accession 0001562180-18-004822

G1 Therapeutics, Inc. · GTHX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Dec 4, 2018

Accepted (ET)

Dec 4, 2018 · 6:10 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001560241

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Dec 4, 2018	M	607	$0.39	A	607	D
Common Stock	Dec 4, 2018	M	9,393	$0.39	A	10,000	D
Common Stock^F2	Dec 4, 2018	S	9,884	$39.3066	D	116	D
Common Stock	Dec 4, 2018	S	116	$40.00	D	0	D
Common Stock^F3	holding	—	—		—	58,282	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Options (Right to Buy)^F4	$0.39	Dec 4, 2018	M	607	D	—	Jan 21, 2024	Common Stock	607	0	D
Stock Options (Right to Buy)^F4	$0.39	Dec 4, 2018	M	9,393	D	—	Jul 11, 2024	Common Stock	9,393	7,969	D

F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2The price represents the weighted average price with a low of $38.99 and a high of $39.545. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
F3These shares are held in the Seth A. Rudnick 2014 GST Trust U/A Dated 03/01/2014 (the "Trust") for the benefit of the Reporting Person's heirs. The Reporting Person's spouse is trustee of the Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F4All shares underlying this option have vested.